1333331-85-3

Basic information

• Product Name: 3-(4-methoxybenzyloxy)pyridin-4(1H)-one
• Synonyms: 3-(4-methoxybenzyloxy)pyridin-4(1H)-one
• CAS NO: 1333331-85-3
• Molecular Weight: 231.251
• Mol File: 1333331-85-3.mol
• Article Data: 2

Chemical Properties

• CAS DataBase Reference: 3-(4-methoxybenzyloxy)pyridin-4(1H)-one(CAS DataBase Reference)
• NIST Chemistry Reference: 3-(4-methoxybenzyloxy)pyridin-4(1H)-one(1333331-85-3)
• EPA Substance Registry System: 3-(4-methoxybenzyloxy)pyridin-4(1H)-one(1333331-85-3)

Safety Data

• Hazardous Substances Data: 1333331-85-3(Hazardous Substances Data)

Upstream product

• 61049-67-0 3-Benzyloxy-4-pyrone 
• 1219-33-6 5-(benzyloxy)-4-oxo-4H-pyran-2-carboxylic acid 
• 824-94-2 p-methoxybenzyl chloride 
• 496-63-9 3-hydroxy-pyran-4-one 
• 501-30-4 5-hydroxy-2-(hydroxymethyl)-4H-pyran-4-one 
• 1333331-84-2 3-[(4-methoxybenzyl)oxy]-4H-pyran-4-one 
• 15771-06-9 5-benzyloxy-2-hydroxymethyl-4H-pyran-4-one 

Downstream Products

• 1333331-89-7 6'-bromo-3-[(4-methoxybenzyl)oxy]-4H-1,2'-bipyridin-4-one 
• 1333331-86-4 4'-iodo-3-[(4-methoxybenzyl)oxy]-4H-1,2'-bipyridin-4-one 
• 1333331-90-0 3'-fluoro-4'-iodo-3-[(4-methoxybenzyl)oxy]-4H-1,2'-bipyridin-4-one 
• 1333331-87-5 {3-[(4-methoxybenzyl)oxy]-4-oxo-4H-1,2'-bipyridin-4-yl}boronic acid 
• 1333331-88-6 3-[(4-methoxybenzyl)oxy]-4'-phenyl-[1,2']bipyridinyl-4-one 
• 1333331-91-1 4'-(5-chloro-1H-pyrrolo[2,3-b]pyridin-4-yl)-3'-fluoro-3-[(4-methoxybenzyl)oxy]-4H-1,2'-bipyridin-4-one 
• 1333329-16-0 4'-(3,4-dichlorophenyl)-3-hydroxy-4H-1,2'-bipyridin-4-one 
• 1333328-89-4 3-hydroxy-1-(2-phenylpyrimidin-4-yl)pyridin-4(1H)-one 

Relevant articles and documents

Synthesis and optimization of N-heterocyclic pyridinones as catechol-O-methyltransferase (COMT) inhibitors

A series of N-heterocyclic pyridinone catechol-O-methyltransferase (COMT) inhibitors were synthesized. Physicochemical properties, including ligand lipophilic efficiency (LLE) and c log P, were used to guide compound design and attempt to improve inhibitor pharmacokinetics. Incorporation of heterocyclic central rings provided improvements in physicochemical parameters but did not significantly reduce in vitro or in vivo clearance. Nevertheless, compound 11 was identified as a potent inhibitor with sufficient in vivo exposure to significantly affect the dopamine metabolites homovanillic acid (HVA) and dihydroxyphenylacetic acid (DOPAC), and indicate central COMT inhibition.